Neuroplasticity Intervention, Amygdala and Insula Retraining (AIR), Significantly Improves Overall Health and Functioning Across Various Chronic Conditions.
{"title":"Neuroplasticity Intervention, Amygdala and Insula Retraining (AIR), Significantly Improves Overall Health and Functioning Across Various Chronic Conditions.","authors":"Alexandra J Bratty","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Chronic conditions, sometimes referred to as functional somatic disorders, such as myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), fibromyalgia (FM), and more recently, long COVID (LC), affect millions of people worldwide. Yet, after decades of research and testing, the etiology and treatment for many of these diseases is still unclear. Recently, a consortium of clinicians and researchers have proposed that while many different chronic conditions exist, the root cause of each may be a similar brain-body connection, as the brain responds to perceived biological threats and transmits danger signals to the body that manifest as somatic symptoms. This hypothesis suggests that treating chronic conditions requires an approach that addresses the neural networks involved. One such method, known as Amygdala and Insula Retraining (AIR), otherwise known as The Gupta Program, has shown promise in recent years for treating such conditions, including ME/CFS, FM, and LC. The present study aimed to demonstrate that AIR could be an effective approach for numerous other chronic illnesses (e.g., Lyme disease, mold illness, mast cell activation syndrome [MCAS]) and others. This novel and exploratory research examined self-reported health and functioning levels before and after using AIR. A series of paired-sample <i>t</i> tests with Bonferroni correction demonstrated that after 3+ months of using AIR (the minimum recommended time for the intervention), participants experienced a significant increase in overall health and functioning for 14 of 16 conditions tested (<i>P</i> < .001 for all but one, which was <i>P</i> = .001) and approached significance for the remaining two conditions (<i>P</i> = .039 and <i>P</i> = .005). Of the 14 signficant findings, 11 had a large effect size and three had a medium effect size. Naturally, this study has limitations. It was a cross-sectional design with a small convenience sample and self-reported data. Future research with larger samples and randomized controlled trials is needed to provide further evidence of AIR's effectiveness. Nonetheless, these preliminary findings suggest that AIR is a viable method for improving the health of people suffering from chronic conditions, and clinicians and researchers might consider incorporating AIR into their protocols for these patients.</p>","PeriodicalId":13593,"journal":{"name":"Integrative medicine","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10886399/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Integrative medicine","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Chronic conditions, sometimes referred to as functional somatic disorders, such as myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), fibromyalgia (FM), and more recently, long COVID (LC), affect millions of people worldwide. Yet, after decades of research and testing, the etiology and treatment for many of these diseases is still unclear. Recently, a consortium of clinicians and researchers have proposed that while many different chronic conditions exist, the root cause of each may be a similar brain-body connection, as the brain responds to perceived biological threats and transmits danger signals to the body that manifest as somatic symptoms. This hypothesis suggests that treating chronic conditions requires an approach that addresses the neural networks involved. One such method, known as Amygdala and Insula Retraining (AIR), otherwise known as The Gupta Program, has shown promise in recent years for treating such conditions, including ME/CFS, FM, and LC. The present study aimed to demonstrate that AIR could be an effective approach for numerous other chronic illnesses (e.g., Lyme disease, mold illness, mast cell activation syndrome [MCAS]) and others. This novel and exploratory research examined self-reported health and functioning levels before and after using AIR. A series of paired-sample t tests with Bonferroni correction demonstrated that after 3+ months of using AIR (the minimum recommended time for the intervention), participants experienced a significant increase in overall health and functioning for 14 of 16 conditions tested (P < .001 for all but one, which was P = .001) and approached significance for the remaining two conditions (P = .039 and P = .005). Of the 14 signficant findings, 11 had a large effect size and three had a medium effect size. Naturally, this study has limitations. It was a cross-sectional design with a small convenience sample and self-reported data. Future research with larger samples and randomized controlled trials is needed to provide further evidence of AIR's effectiveness. Nonetheless, these preliminary findings suggest that AIR is a viable method for improving the health of people suffering from chronic conditions, and clinicians and researchers might consider incorporating AIR into their protocols for these patients.
慢性疾病,有时也被称为功能性躯体疾病,如肌痛性脑脊髓炎/慢性疲劳综合征(ME/CFS)、纤维肌痛(FM)以及最近出现的长 COVID(LC),影响着全球数百万人。然而,经过数十年的研究和测试,许多此类疾病的病因和治疗方法仍不明确。最近,一个由临床医生和研究人员组成的联盟提出,虽然存在许多不同的慢性疾病,但每种疾病的根源可能都是类似的脑身联系,因为大脑会对感知到的生物威胁做出反应,并将危险信号传递给身体,表现为躯体症状。这一假设表明,治疗慢性疾病需要一种能够解决相关神经网络问题的方法。近年来,一种名为 "杏仁核和脑岛再训练(AIR)"(又称 "古普塔计划")的方法已显示出治疗此类疾病(包括 ME/CFS、FM 和 LC)的前景。本研究旨在证明 AIR 是治疗其他多种慢性疾病(如莱姆病、霉菌病、肥大细胞活化综合征 [MCAS])及其他疾病的有效方法。这项新颖的探索性研究考察了使用空气疗法前后自我报告的健康和功能水平。一系列经 Bonferroni 校正的配对样本 t 检验表明,在使用 AIR 3 个多月后(干预的最短建议时间),参与者的总体健康和功能水平在 16 种受测病症中的 14 种有显著提高(除一种病症外,其他病症的 P < .001,即 P = .001),其余两种病症的 P 接近显著性(P = .039 和 P = .005)。在 14 个显著性结果中,11 个具有较大的效应大小,3 个具有中等效应大小。当然,这项研究也有局限性。这是一项横断面设计,采用的是小样本和自我报告数据。未来的研究需要更大的样本和随机对照试验来进一步证明 AIR 的有效性。尽管如此,这些初步研究结果表明,AIR 是改善慢性病患者健康状况的一种可行方法,临床医生和研究人员可以考虑将 AIR 纳入他们对这些患者的治疗方案中。